In an elderly patient with dementia who is experiencing new or worsening confusion while on memantine (titrated to 20 mg per day), should the medication be continued for its memory benefits?

Discontinue Memantine When It Causes Confusion

If memantine is causing new or worsening confusion in your patient with dementia, you should discontinue it—this is explicitly listed as an intolerable side effect warranting discontinuation, regardless of any theoretical memory benefits. The 2020 Canadian Consensus Conference guidelines specifically identify "confusion, dizziness, falls" as intolerable side effects that are clear indications to stop memantine 1111.

Why This Matters More Than "Memory Benefits"

While memantine is FDA-approved for moderate-to-severe dementia 2, the reality is nuanced:

• The cognitive benefits are modest at best: High-certainty evidence shows memantine provides only 3.11 points improvement on the Severe Impairment Battery in moderate-to-severe AD—a statistically significant but clinically small effect 3
• Confusion is a recognized adverse effect: The FDA label explicitly lists confusion among the most common adverse reactions (≥5% incidence) 2, and it appears as a reason to discontinue in clinical guidelines 111
• Quality of life trumps test scores: A patient experiencing worsening confusion has objectively worse quality of life and increased fall risk, which outweighs marginal improvements on cognitive testing

The Guideline Framework for Discontinuation

The 2020 Canadian guidelines provide clear criteria for stopping memantine 11:

Discontinue if there is:

• Development of intolerable side effects (specifically listing confusion, dizziness, falls)
• No clinically meaningful benefit observed during treatment
• Severe/end-stage dementia with poor quality of life

Your patient meets the first criterion definitively.

Important Caveats About Memantine and Confusion

Rule out other causes first: Before attributing confusion solely to memantine, ensure you've excluded:

• Delirium from intercurrent illness
• Recent medication changes (especially anticholinergics, benzodiazepines)
• Metabolic derangements
• Urinary tract infection or other acute medical issues

Consider the diagnosis: One case report documented severe worsening of confusion and hallucinations in a patient initially diagnosed with AD who was actually suffering from Lewy body dementia—memantine exacerbated his symptoms 4. However, a small trial in DLB showed memantine could be beneficial 5, so the picture is mixed.

How to Discontinue Safely

Gradual taper is recommended 111:

• Reduce dose by 50% every 4 weeks
• Continue until reaching the initial starting dose (5 mg daily)
• After 4 weeks at starting dose, discontinue completely
• Monitor for rebound worsening of cognition or behavior

For your patient on 20 mg daily:

• Week 1-4: Reduce to 10 mg daily
• Week 5-8: Reduce to 5 mg daily
• Week 9-12: Discontinue

Monitor during and after discontinuation: If you observe clinically meaningful worsening of cognition, function, or neuropsychiatric symptoms that appears related to stopping memantine, consider reinitiating 11.

The Bottom Line on "Memory Benefits"

The evidence shows memantine's cognitive benefits are real but small—approximately 2-3 points on various cognitive scales 3. This translates to minimal functional impact in most patients. When balanced against causing confusion (which directly impairs function and increases fall risk), the harm clearly outweighs benefit.

The 2008 American College of Physicians guideline emphasizes this principle: treatment decisions should balance modest benefits against harms, and "if slowing decline is no longer a goal, treatment with memantine or a cholinesterase inhibitor is no longer appropriate" 6. A confused, agitated patient falling at home has objectively worse outcomes than one who is slightly more cognitively impaired but stable and safe.

Do not continue a medication that is causing harm based on hope for theoretical benefits that are, at best, marginal.